Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals Inc (Form: 4, Received: 06/21/2017 20:49:48)
FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

GREAT POINT PARTNERS LLC
2. Issuer Name and Ticker or Trading Symbol

Adamas Pharmaceuticals Inc [ ADMS ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

165 MASON STREET, 3RD FLOOR, 
3. Date of Earliest Transaction (MM/DD/YYYY)

6/19/2017
(Street)

GREENWICH, CT 06830
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   6/19/2017     S    350000   (1) D $17.0505   2251351   (2) I   Investment Mgr.   (3)
Common Stock   6/20/2017     S   V 20000   (4) D $17.3467   2231351   (5) I   Investment Mgr.   (3)
Common Stock   6/21/2017     S   V 10000   (6) D $17.4365   2216351   (7) I   Investment Mgr.   (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Consists of 94,851 shares owned by Biomedical Value Fund, L.P. ("BVF"), 145,713 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 103,098 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 6,338 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
(2)  Consists of 610,121 shares owned by Biomedical Value Fund, L.P. ("BVF"), 937,287 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 663,176 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,767 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
(3)  Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.
(4)  Consists of 5,420 shares owned by Biomedical Value Fund, L.P. ("BVF"), 8,327 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 5,891 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 362 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
(5)  Consists of 604,701 shares owned by Biomedical Value Fund, L.P. ("BVF"), 928,960 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 657,285 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,405 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
(6)  Consists of 4,065 shares owned by Biomedical Value Fund, L.P. ("BVF"), 6,245 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 4,418 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 272 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
(7)  Consists of 600,636 shares owned by Biomedical Value Fund, L.P. ("BVF"), 922,715 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 652,867 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,133 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
GREAT POINT PARTNERS LLC
165 MASON STREET, 3RD FLOOR
GREENWICH, CT 06830

X

JAY JEFFREY R
GREAT POINT PARTNERS, LLC
165 MASON STREET, 3RD FLOOR
GREENWICH, CT 06830

X

KROIN DAVID
C/O GREAT POINT PARTNERS LLC
165 MASON STREET, 3RD FLOOR
GREENWICH, CT 06830

X


Signatures
Great Point Partners, LLC /s/ Dr. Jeffrey R. Jay, M.D., Senior Managing Member 6/21/2017
** Signature of Reporting Person Date

/s/ Dr. Jeffrey R. Jay, M.D. 6/21/2017
** Signature of Reporting Person Date

/s/ David Kroin 6/21/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.